Grifols (GRFS) Assets Average (2009 - 2025)
Grifols (GRFS) posted Assets Average of $22.9 billion for Q4 2025, up 0.79% quarter-over-quarter from $22.7 billion in Q4 2024, and up 0.79% year-on-year from $22.7 billion in Q4 2024.
Grifols (GRFS) Assets Average (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Assets Average for 15 consecutive years, with $22.9 billion the latest figure, recorded in Q4 2025.
- Assets Average for Q4 2025 came in at $22.9 billion, up 0.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.9 billion (up 0.79% YoY), and the FY2025 annual result was $11.5 billion, up 9184.56% from the prior year.
- Assets Average was $22.9 billion for Q4 2025 at Grifols, up from $22.7 billion in the prior quarter.
- Over five years, Assets Average peaked at $22.9 billion in Q4 2025 and troughed at $20.1 billion in Q4 2021.
- Average Assets Average over 5 years is $21.9 billion, with a median of $22.1 billion recorded in 2023.
- Year-over-year, Assets Average rose 10.21% in 2021 and gained 0.79% in 2025.
- Over 5 years, Assets Average stood at $20.1 billion in 2021, then rose by 8.57% to $21.8 billion in 2022, then rose by 1.34% to $22.1 billion in 2023, then increased by 2.74% to $22.7 billion in 2024, then climbed by 0.79% to $22.9 billion in 2025.
- Per Business Quant data, the three most recent Assets Average figures were $22.9 billion in Q4 2025, $22.7 billion in Q4 2024, and $22.1 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 22.91 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.91 Bn |
| Dec 31, 2024 | 22.73 Bn |
| Dec 31, 2023 | 22.12 Bn |
| Dec 31, 2022 | 21.83 Bn |
| Dec 31, 2021 | 20.11 Bn |
| Dec 31, 2020 | 18.24 Bn |
| Sep 30, 2020 | 17.91 Bn |
| Mar 31, 2020 | 17.38 Bn |
| Dec 31, 2019 | 16.41 Bn |
| Sep 30, 2019 | 15.42 Bn |
| Mar 31, 2019 | 14.73 Bn |
| Dec 31, 2018 | 13.97 Bn |
| Sep 30, 2018 | 13.67 Bn |
| Jun 30, 2018 | 15.05 Bn |
| Mar 31, 2018 | 14.65 Bn |
| Dec 31, 2017 | 12.54 Bn |
| Dec 31, 2016 | 10.81 Bn |
| Sep 30, 2016 | 10.73 Bn |
| Jun 30, 2016 | 10.48 Bn |
| Mar 31, 2016 | 10.36 Bn |